Alexion lines up a $60M option to buy Fortress-incubated biotech focused on a lucrative rare blood disease
Now that Alexion has secured an FDA approval for Ultomiris, the follow-on for its flagship drug Soliris, the biotech is back on the hunt for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
